Smart scan guides lymphoma therapy, spares unneeded drugs

NCT ID NCT03233347

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 29 times

Summary

This study tests a personalized approach for people with early-stage Hodgkin lymphoma (stages I-II). Doctors use PET scans to see how well the cancer responds to initial chemotherapy, then adjust the treatment plan—adding or skipping certain drugs—to improve outcomes and reduce side effects. About 82 participants will receive a combination of chemotherapy and immunotherapy, with the goal of increasing survival and keeping the cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE IB HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Carolinas Medical Center/Levine Cancer Institute

    Charlotte, North Carolina, 28203, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • University of Washington Medical Center - Montlake

    Seattle, Washington, 98195, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.